Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @evaluatepharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @evaluatepharma
-
EvaluatePharma proslijedio/la je Tweet
A big bet for
$LLY: outcome studies of GLP-1 agonists in diabetes cost on avg $860m, and the huge CVOT for tirzepatide could set a new record. Check out our look at R&D cost estimates from@evaluatepharma: https://www.evaluate.com/vantage/articles/analysis/spotlight/tirzepatides-time-shine-lilly …$NVOpic.twitter.com/oELkBNbwca
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020: http://ow.ly/FbU950ydWWm
#alzheimers#anemia#FDA#drugapprovalspic.twitter.com/oICt3prbPn
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
What are the interesting pharma pipeline deals to look out for in 2020? https://info.evaluate.com/V20PREV.html
#drugpipelinepic.twitter.com/zpdc6RJivtHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The second half of 2019 saw half as many innovative medical devices approved as the first: http://ow.ly/PNut50ycVRw
#medtechpic.twitter.com/r2dLOJHBmb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thanks to several successful oncology franchises,
@AstraZeneca is the pharma company with the biggest projected top-line growth in 2020. Download the Vantage 2020 Preview to learn more: http://ow.ly/d5aJ50xTG0b#oncology#drugsalespic.twitter.com/yCja4B7XZb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound: http://ow.ly/O0F950ycV2D
#pharmapic.twitter.com/Q6PusO0wxH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead has targeted the Wuhan coronavirus with remdesivir, resulting in its stock increasing 4%, but the omens from previous studies are not wholly positive (via
@LizVantage): http://ow.ly/VTiH50ycUV4#coronavirus#vaccinesHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ensure your 2020 plans have factored in the key risks and opportunities facing pharma this year. Download your free copy of the Vantage 2020 Preview for detailed analysis of the year ahead: http://ow.ly/dIqC50ybFc5 pic.twitter.com/HPjV8valtA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals: https://www.evaluate.com/vantage/articles/data-insights/ipo/last-ditch-rally-saves-2019-float-tally …
#pharma#IPOpic.twitter.com/yKKEnoJWHf
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Keytruda continues to be the marketed drug with the most expensive ongoing clinical programme, while oncology is the focus of most spending. Find out more in the Vantage 2020 Preview: http://ow.ly/eLhQ50xPVWu
#oncology#keytrudapic.twitter.com/r8IL2B4pAI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Evaluate is at the 5th Global Independent Research Conference in Wimpole Street today. Come and meet the team to understand how EvaluatePharma can enhance investment returns for buy-side.pic.twitter.com/5eUzp4xqPZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
EvaluatePharma proslijedio/la je Tweet
Huge move from
$LLY with GIP/GLP-1 tirzepatide, to start 12,500 patient CVOT vs Trulicity, assessing non-inferiority and superiority. Surpass pivotal programme starts reporting later this year. Consensus for 2024 sales has been climbing, according to@evaluatepharmapic.twitter.com/jgFTcQMVkv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Most read on
@Vantageanalysis this week: New Pfizer, same problem:https://www.evaluate.com/vantage/articles/news/corporate-strategy/new-pfizer-same-problem …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer: http://ow.ly/AX5P50y9hST
#Medtech#RoboticSurgerypic.twitter.com/HJICbnNb7M
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
What is the outlook for investment in pharma during 2020? Download your free copy of the Vantage 2020 Preview for the full analysis: http://ow.ly/oGZB50xPUz6
#Pharmapic.twitter.com/qqC3HNGxMgHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're proud to announce we've been shortlisted for an Apprenticeship Connect Employer of the Year award
. Thank you to all our current and past apprentices for their valuable contributions to life at Evaluate. @ApprenticeshipCpic.twitter.com/xlBeHkT7sa
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
EvaluatePharma proslijedio/la je Tweet
***AC Awards Shortlist Announced*** Good Luck!
@BlueEngineering@spirehealthcare@PimlicoPlumbers@NSTRrecruitment@PrimaryPPACover@SeekSocialTeam@conranestates@ProjectusJobs@walmsleys@evaluatepharma@LETTA_Trust@urgcareers@Chestertons@helpinghands@PearsonEdexcelpic.twitter.com/nwBlycHnfFHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
EvaluatePharma proslijedio/la je Tweet
Astra has spent a great deal on developing Brilinta, and it will take time to recoup that cost. Here, Vantage uses
@evaluatepharma Vision data to estimate just how expensive the process has been.https://www.evaluate.com/vantage/articles/data-insights/other-data/cost-astrazeneca-building-brilinta …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
EvaluatePharma proslijedio/la je Tweet
$PFE on Q4 call confirms anti-NGF tanezumab was filed with FDA in December, waiting for acceptance. Still sees "significant potential" in osteo arthritis. Sellside consensus virtually zero, according to@evaluatepharma, so a big wait and see here.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The amount of medtech venture capital deals has been declining significantly over the last decade: http://ow.ly/ZAFQ50y8OL5
#medtech#venturecapitalpic.twitter.com/RVQ38GML6W
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.